Also listed on Allergan, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Mar 11, 2029 · High confidence
20-year base term ends Mar 9, 2029
Held by Allergan Sales, LLC
Filed Mar 9, 2009 as application 12/400,145 · Granted Oct 2, 2018
Base term plus 2 days of patent term adjustment (USPTO delay)
Today
2009
2029
Clock starts
Mar 9, 2009
Mar 9, 2009
Term ends
Mar 11, 2029
Mar 11, 2029
Granted
Oct 2, 2018
Oct 2, 2018
base term
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
2
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
28
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 2 days past its 20-year base term on prosecution delay. 2 of 2 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 9, 2009, when this application, 12/400,145, was filed | Mar 9, 2029 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +2 days, USPTO patent term adjustment record | Mar 11, 2029 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Mar 11, 2029 | High confidence |
This family
| US 8,604,222 | Lapsed on the fee record Dec 2025 | Dec 2025 |
| US 8,246,950 | In force Feb 2028 | Feb 2028 |
| US 8,221,747 | In force Feb 2028 | Feb 2028 |
| US 8,293,229 | In force Mar 2031 | Mar 2031 |
| US 7,541,384 | In force Jun 2028 | Jun 2028 |
| US 10,087,493 | this patent Mar 2029 | Mar 2029 |
| US 8,217,083 | In force Jun 2028 | Jun 2028 |
| US 8,784,884 | In force Aug 2031 | Aug 2031 |
8 of 28 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Oct 14, 2013 Reel 31401, frame 389 | Tijssen, Peter; Szelei, Jozsef; Zadori, Zoltan | Institut National de la Recherche Scientifique | Assignment of Assignor's Interest |
| Oct 14, 2013 Reel 31401, frame 475 | Institut National de la Recherche Scientifique | Aptalis Pharma Canada, Inc. | Assignment of Assignor's Interest |
| Oct 31, 2013 Reel 31531, frame 488 | Aptalis Pharma Canada Inc.; Aptalis Pharma US, Inc.; Aptalis Pharmatech, Inc. | Bank of America, N.A., as Administrative Agent | Patent Security Agreement |
| Jan 31, 2014 Reel 32149, frame 111 | Bank of America, N.A., as Administrative Agent | Aptalis Pharma US, Inc.; Aptalis Pharmatech, Inc.; Aptalis Pharma Canada Inc. | Termination and Release |
| Jan 31, 2014 reel/frame not recorded | Bank of America, N.A., as Administrative Agent | Aptalis Pharma US, Inc. | Termination and Release |
| Jan 31, 2014 reel/frame not recorded | Bank of America, N.A., as Administrative Agent | Aptalis Pharmatech, Inc. | Termination and Release |
| Jan 31, 2014 reel/frame not recorded | Bank of America, N.A., as Administrative Agent | Aptalis Pharma Canada Inc. | Termination and Release |
| Mar 18, 2016 Reel 38037, frame 424 | Aptalis Pharma Canada Inc. | Aptalis Pharma Canada ULC | Change of Name |
| Sep 23, 2019 Reel 50456, frame 734 | Aptalis Pharma Canada ULC | Aptalis Pharma US, Inc. | Assignment of Assignor's Interest |
| Sep 23, 2019 Reel 50456, frame 816 | Aptalis Pharma US, Inc. | Allergan Sales, LLC | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Mar 2029
Term ends Mar 11, 2029. No further fees fall due before then
Note
The 2 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
69
later US patents cite this one
That is top 5% of utility patents granted in 2018 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.